Barclays’s Ironwood Pharmaceuticals IRWD Stock Holding History

Barclays’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-280,800	Closed	-$2.45M	–	5083
2024 Q1	$2.45M	Buy	280,800 +165,000	+142%	+$2M	﹤0.01%	2399
2023 Q4	$1.32M	Sell	115,800 -48,600	-30%	-$481K	﹤0.01%	3233
2023 Q3	$1.58M	Buy	+164,400	New	+$1.61M	﹤0.01%	2029
2017 Q4	–	Sell	-1,194	Closed	-$16K	–	7001
2017 Q3	$16K	Buy	+1,194	New	+$16.4K	﹤0.01%	5906
2016 Q2	–	Sell	-119,400	Closed	-$1M	–	6461
2016 Q1	$1M	Buy	+119,400	New	+$985K	﹤0.01%	2521
2013 Q3	–	Sell	-17,910	Closed	-$149K	–	7505
2013 Q2	$149K	Buy	+17,910	New	+$217K	﹤0.01%	5455

Other funds holding IRWD

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Barclays's IRWD Position: Q3 2026 in Review

Barclays increased its Ironwood Pharmaceuticals (IRWD) stake by 24% in Q3 2026, buying an estimated $98.6K and bringing the position to 123,736 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #3474.

Barclays first reported a position in IRWD in Q2 2013 and has held it in 54 quarters since. The position peaked at $6.32M in Q4 2023. 112 funds tracked by Wall St. Rank hold IRWD as of Q3 2026.

Barclays held 123,736 shares of Ironwood Pharmaceuticals worth $491K as of Q3 2026.
Barclays bought 23,613 Ironwood Pharmaceuticals shares in Q3 2026, an estimated $98.6K.
Ironwood Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3474 holding.
Barclays first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
Barclays's Ironwood Pharmaceuticals position peaked at $6.32M in Q4 2023.
112 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.